Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperthyroidism. Current treatment guidelines

N J Gittoes1, J A Franklyn

  • 1Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, England.

Drugs
|April 30, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

National Osteoporosis Society practical clinical guideline on vitamin D and bone health.

Maturitas·2014
Same author

Fear of medication side effects is a barrier to optimal osteoporosis care.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2014
Same author

Triiodothyronine regulates angiogenic growth factor and cytokine secretion by isolated human decidual cells in a cell-type specific and gestational age-dependent manner.

Human reproduction (Oxford, England)·2014
Same author

Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors.

The Journal of clinical endocrinology and metabolism·2013
Same author

Expression and function of thyroid hormone transporters in the microvillous plasma membrane of human term placental syncytiotrophoblast.

Endocrinology·2012
Same author

PTTG-binding factor (PBF) is a novel regulator of the thyroid hormone transporter MCT8.

Endocrinology·2012
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Hyperthyroidism, often caused by Graves' disease or toxic nodular goiters, can be treated with antithyroid drugs, surgery, or radioiodine. Radioiodine is increasingly favored, especially for toxic nodular goiters, offering an effective treatment option.

Area of Science:

  • Endocrinology
  • Internal Medicine
  • Nuclear Medicine

Background:

  • Hyperthyroidism affects approximately 2% of women and 0.2% of men.
  • Graves' disease, an autoimmune disorder, and toxic nodular goiters are primary causes.
  • Treatment options include antithyroid drugs, surgery, and radioiodine therapy.

Purpose of the Study:

  • To review the established and emerging treatment modalities for hyperthyroidism.
  • To compare the efficacy and limitations of antithyroid drugs, surgery, and radioiodine.
  • To highlight the growing role of radioiodine as a first-line treatment.

Main Methods:

  • Review of current medical literature on hyperthyroidism treatments.
  • Analysis of treatment outcomes and side effects for each modality.

Related Experiment Videos

  • Comparison of radioiodine, antithyroid drugs, and surgical interventions.

    • Main Results:

    • Antithyroid drugs can induce remission in Graves' disease but are not curative for toxic nodular goiters.
    • Radioiodine is effective for toxic nodular goiters and is increasingly used for Graves' disease.
    • Radioiodine is well-tolerated, with hypothyroidism as a potential long-term sequela; it is contraindicated in children, pregnancy, and lactation.

    Conclusions:

    • All three main treatments for hyperthyroidism are effective, but none offer an absolute cure.
    • Radioiodine is the preferred treatment for toxic nodular goiter hyperthyroidism.
    • Surgery has specific indications, primarily for compressive symptoms or when other treatments are refused.